Helus Pharma said its chemically modified psychedelic candidate improved depression symptoms in a Phase 3 trial but also reported serious adverse events that raise safety questions. The company described statistically significant improvements on the MADRS scale at six and 12 weeks versus placebo. The follow-through risk for the program will likely center on the safety signal quality—severity, duration, and whether the events were mechanistically expected or confounded by background therapies. For investors, the question becomes whether benefit magnitude can offset tolerability concerns in a label-seeking trial design. As psychedelics expand into mainstream psychiatry trials, regulators and payers will scrutinize the overall risk-benefit profile more tightly than in earlier-stage studies.